Screener
Arcutis Biotherapeutics, Inc. ARQT Cash, Cash Equivalents, and Marketable Securities
Cash, Cash Equivalents, and Marketable Securities at other companies
Other financials
Where this comes from
Reported directly by Arcutis Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecurities.
The source filing: Arcutis Biotherapeutics, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:21 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001787306-26-000051
| Line item | Amortizedcost | Unrealizedgains | Unrealizedlosses | Estimatedfair value |
|---|---|---|---|---|
| Money market funds and cash | $28,658 | — | — | $28,658 |
| Certificates of deposit | 5,463 | — | — | 5,463 |
| Total cash and cash equivalents | $34,121 | — | — | $34,121 |
| Marketable securities: | ||||
| Commercial paper | $16,584 | — | $(17) | $16,567 |
| Corporate debt securities | 94,325 | 1 | (192) | 94,134 |
| U.S. Treasury and agency securities | 93,856 | — | (126) | 93,730 |
| Total marketable securities | $204,765 | $1 | $(335) | $204,431 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Arcutis Biotherapeutics, Inc.'s cash, cash equivalents, and marketable securities?
- Arcutis Biotherapeutics, Inc. (ARQT) reported cash, cash equivalents, and marketable securities of $204.43M in Q2 2026.
- How has Arcutis Biotherapeutics, Inc.'s cash, cash equivalents, and marketable securities changed year-over-year?
- Arcutis Biotherapeutics, Inc.'s cash, cash equivalents, and marketable securities increased by 73.1% year-over-year, from $118.08M to $204.43M.
- What is the long-term trend for Arcutis Biotherapeutics, Inc.'s cash, cash equivalents, and marketable securities?
- Over 5 years (2020 to 2025), Arcutis Biotherapeutics, Inc.'s cash, cash equivalents, and marketable securities has grown at a -4.1% compound annual growth rate (CAGR), from $219.36M to $178.08M.
- What does cash, cash equivalents, and marketable securities mean?
- This represents the most liquid assets held by the company, including cash on hand, bank deposits, and short-term investments that can be readily converted into cash. It serves as the primary buffer for operational liquidity and potential capital allocation activities. Investors monitor this to assess the company's ability to meet short-term obligations and fund growth initiatives.
Ask your AI about Arcutis Biotherapeutics, Inc.'s cash, cash equivalents, and marketable securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude